11月7日,Nurix Therapeutics Inc公布了口服CBL-B抑制剂NX-1607的首个人体临床试验的新转化数据,结果显示该药物具有免疫激活作用,并能重塑肿瘤微环境。
11月7日,Nurix Therapeutics Inc公布了口服CBL-B抑制剂NX-1607的首个人体临床试验的新转化数据,结果显示该药物具有免疫激活作用,并能重塑肿瘤微环境。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.